Journal
NEURON
Volume 74, Issue 6, Pages 964-966Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2012.06.001
Keywords
-
Categories
Funding
- NINDS NIH HHS [R01 NS074312, R01 NS049501] Funding Source: Medline
Ask authors/readers for more resources
Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's disease. In this issue of Neuron, Kordasiewicz et al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
